 |
|
|
|
This month we would like to know...
Which of the following describes your health system current (or near-future) stance on pharmacogenomics testing?
| a) |
We do not use them and are not considering using them. |
| |
|
| b) |
We are discussing their use but their future is not yet known. |
| |
|
| c) |
We are discussing their use and plan to begin using them in the near future. |
| |
|
| d) |
We are currently using them or in the implementation phase. |
| |
|
| e) |
Other |
Vote in our survey, and see what other P&T committee members have to say.
 |
|
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary.
Formulary
Digital Edition
Click here to view the current edition.
Click here to subscribe. |
|
|
|
|
FDA approves first oral MS treatment
FDA has approved fingolimod (Gilenya, Novartis), 0.5 mg daily, as a first-line treatment to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS). It is the first oral MS treatment approved in the United States. More... |
|
| |
GBCAs to include warning on NSF risk
FDA is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of nephrogenic systemic fibrosis (NSF), a rare and potentially fatal condition, if the drug is administered to certain patients with kidney disease. More... |
|
|
| |
| |
Prophylactic antivirals reduce corneal disease recurrences
Individuals with ocular herpes simplex virus (HSV) treated with prophylactic oral antibiotics appear to be at a lower risk of recurrence of epithelial keratitis, stromal keratitis, conjunctivitis, and blepharitis, according to research published in the September issue of the Archives of Ophthalmology, as reported by HealthDay News. More... |
FDA grants ipilimumab priority review
Ipilimumab (Bristol-Myers Squibb) intended to treat patients with stage III or IV metastatic melanoma has been granted priority review by FDA. More... |
Giving more people statins could cost effectively prevent heart attacks
Giving cholesterol-lowering statin drugs to more people could be a cost-effective way of preventing heart attacks, US researchers said Sept. 27, as reported by Reuters. The study was published in Circulation. More... |
No benefit to early chemo in ovarian cancer relapse
For women whose ovarian cancer has been in remission, restarting chemotherapy early on the basis of heightened CA125 concentration does not improve survival compared with postponing treatment until symptoms of relapse appear, according to a study published in the Oct. 2, cancer-themed issue of The Lancet. More... |
DMARDs, glucocorticoids, biologics similar for treatment of RA
Treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, biologics, or a combination of these agents significantly reduces radiographic evidence of joint destruction, with no advantage seen for patients whose treatment includes biologics, according to research published in the October issue of Arthritis & Rheumatism. More... |
FDA orders halt to production and marketing of unapproved single-ingredient oral colchicine
FDA has requested that all companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF), stop the manufacturing of this drug. More... |
Oral naproxen, sumatriptan provides comparable post-emergency department recurrent headache relief
For patients experiencing headache recurrence within 48 hours of an emergency department discharge, naproxen 500 mg or sumatriptan 100 mg taken orally relieves recurrent primary headache (including migraine, tension type, and cluster headaches) pain comparably, according to a report published in a recent issue of Annals of Emergency Medicine. More... |
Schizophrenia study stopped early due to success
Because of successfully meeting efficacy criteria at a protocol-specified interim analysis, an independent data monitoring committee (IDMC) has recommended the early termination of Otsuka’s phase 3, 52-week, placebo-controlled, intramuscular (IM) depot aripiprazole trial. More... |
|
|
|
|
|
|
| |
